Table 1 Clinicopathological characteristics of all patients (N = 390)
Characteristic | Value or N (%) |
|---|---|
Age (years) | |
 Median | 67 |
 Range | 31 − 88 |
Sex | |
 Female | 81 (20.8%) |
 Male | 309 (79.2%) |
ECOG PS | |
 0 | 144 (36.9%) |
 1 | 213 (54.6%) |
 2 | 28 (7.2%) |
 3 | 5 (1.3%) |
Line of treatment | |
 First | 95 (24.4%) |
 Second | 121 (31.0%) |
 Third or higher | 174 (44.6%) |
Smoking history | |
 Never-smoker | 68 (17.4%) |
 Ex-smoker | 196 (50.3%) |
 Current smoker | 126 (32.3%) |
Clinical stage | |
 Advanced | 305 (78.2%) |
 Recurrent | 85 (21.8%) |
Mutation status (EGFR or ALK) | |
 Wild-type | 280 (71.8%) |
 Mutationa | 46 (11.8%) |
 Unknown | 64 (16.4%) |
Histology | |
 Adenocarcinoma | 249 (63.8%) |
 Squamous cell carcinoma | 106 (27.2%) |
 Others or unknownb | 35 (9.0%) |
Immune checkpoint inhibitor | |
 Nivolumab | 223 (57.2%) |
 Pembrolizumab | 167 (42.8%) |
PD-L1 tumor proportion score | |
  < 1% | 51 (13.1%) |
  ≥ 1 and < 50% | 82 (21.0%) |
  ≥ 50% | 128 (32.8%) |
 Unknown | 129 (33.1%) |
Body mass index (kg/m2) | |
  <  22 | 213 (54.6%) |
  ≥ 22 | 177 (45.4%) |
Statin therapy | |
 No | 337 (86.4%) |
 Yes | 53 (13.6%) |